Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Oral ONC201 in Adult Recurrent Glioblastoma

NCT02525692 is registered in ClinicalTrials.gov with Jazz Pharmaceuticals as lead sponsor.

NCT NCT02525692
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT02525692 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Oral ONC201 in Adult Recurrent Glioblastoma
Lead sponsor
Jazz Pharmaceuticals
Phase
Phase 2
Overall status
Terminated
Start date
January 31, 2016
Completion date
April 17, 2023
Enrollment
84 (actual)
Sites
5

Conditions

As the registry lists them; a condition with its own page is linked.

basal ganglia glioma, diffuse midline glioma, glioblastoma, h3 k27m glioma, infratentorial glioma, thalamic glioma